Piper Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $11 from $7 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Strong Performance and Future Prospects Drive Buy Rating for Adaptive Biotechnologies
- Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank
- Stable Performance and Strategic Guidance Support Hold Rating for Adaptive Biotechnologies
- Adaptive Biotechnologies Shines in 2024 Earnings Call
- Adaptive Biotechnologies Reports 2024 Financial Performance